STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancer

Elife. 2024 Apr 4:13:RP92559. doi: 10.7554/eLife.92559.

Abstract

Oncogenic mutations in KRAS are among the most common in cancer. Classical models suggest that loss of epithelial characteristics and the acquisition of mesenchymal traits are associated with cancer aggressiveness and therapy resistance. However, the mechanistic link between these phenotypes and mutant KRAS biology remains to be established. Here, we identify STAT3 as a genetic modifier of TGF-beta-induced epithelial to mesenchymal transition. Gene expression profiling of pancreatic cancer cells identifies more than 200 genes commonly regulated by STAT3 and oncogenic KRAS. Functional classification of the STAT3-responsive program reveals its major role in tumor maintenance and epithelial homeostasis. The signatures of STAT3-activated cell states can be projected onto human KRAS mutant tumors, suggesting that they faithfully reflect characteristics of human disease. These observations have implications for therapeutic intervention and tumor aggressiveness.

Keywords: KRAS; STAT3; cancer biology; cancer dependency; epithelial carcinogenesis; mouse.

MeSH terms

  • Cell Line, Tumor
  • Epithelial-Mesenchymal Transition / genetics
  • Humans
  • Pancreas / metabolism
  • Pancreatic Neoplasms* / pathology
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Proto-Oncogene Proteins p21(ras) / metabolism
  • STAT3 Transcription Factor / genetics
  • STAT3 Transcription Factor / metabolism
  • Transforming Growth Factor beta* / metabolism

Substances

  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)
  • STAT3 protein, human
  • STAT3 Transcription Factor
  • Transforming Growth Factor beta
  • TGFB1 protein, human

Associated data

  • Dryad/10.5061/dryad.1vhhmgqzc
  • GEO/GSE132582